DK0626367T3 - (7S)-7- (2R)-2-(3-chlorphenyl)-2-hydroxyethylamino -5,6,7,8-tetrahydronapthalen-2-yloxyeddikesyre og farmaceutisk acceptable salte deraf med beta3-adrenerg agonistvirkning, farmaceutiske præparater og laboratoriereagenser som indeholder den. - Google Patents
(7S)-7- (2R)-2-(3-chlorphenyl)-2-hydroxyethylamino -5,6,7,8-tetrahydronapthalen-2-yloxyeddikesyre og farmaceutisk acceptable salte deraf med beta3-adrenerg agonistvirkning, farmaceutiske præparater og laboratoriereagenser som indeholder den.Info
- Publication number
- DK0626367T3 DK0626367T3 DK94401163.4T DK94401163T DK0626367T3 DK 0626367 T3 DK0626367 T3 DK 0626367T3 DK 94401163 T DK94401163 T DK 94401163T DK 0626367 T3 DK0626367 T3 DK 0626367T3
- Authority
- DK
- Denmark
- Prior art keywords
- agonist activity
- hydroxyethylamino
- chlorophenyl
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- 239000000048 adrenergic agonist Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- PLYWAKPAFSZPAL-HKUYNNGSSA-N 2-[[(7s)-7-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetic acid Chemical compound C1([C@H](CN[C@@H]2CC3=CC(OCC(O)=O)=CC=C3CC2)O)=CC=CC(Cl)=C1 PLYWAKPAFSZPAL-HKUYNNGSSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93401375A EP0627407A1 (de) | 1993-05-28 | 1993-05-28 | (7S)-7-(2R)-2(3-Chlorophenyl)-2-hydroxethylamino-5,6,7,8-Tetrahydronaphthalen-2-yloxy-Essigsäure, ihre pharmazeutisch akzeptablen Salze, mit Beta-3-adrenergischer agonistischer Aktivität und diese enthaltende pharmazeutische Zusammensetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0626367T3 true DK0626367T3 (da) | 1997-10-27 |
Family
ID=8214713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94401163.4T DK0626367T3 (da) | 1993-05-28 | 1994-05-26 | (7S)-7- (2R)-2-(3-chlorphenyl)-2-hydroxyethylamino -5,6,7,8-tetrahydronapthalen-2-yloxyeddikesyre og farmaceutisk acceptable salte deraf med beta3-adrenerg agonistvirkning, farmaceutiske præparater og laboratoriereagenser som indeholder den. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5488151A (de) |
| EP (2) | EP0627407A1 (de) |
| JP (1) | JP3939369B2 (de) |
| AT (1) | ATE151405T1 (de) |
| DE (1) | DE69402463T2 (de) |
| DK (1) | DK0626367T3 (de) |
| ES (1) | ES2103113T3 (de) |
| GR (1) | GR3023729T3 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197993B1 (en) | 1996-07-02 | 2001-03-06 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient |
| EP0845451A4 (de) * | 1995-07-26 | 1999-10-13 | Ono Pharmaceutical Co | Naphthyloxoessigsäure-derivate und medikamente die diese als aktive bestandteile enthalten |
| DK0764632T3 (da) * | 1995-09-21 | 2001-09-24 | Lilly Co Eli | Selektive beta3-adrenerge agonister |
| ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| US6075040A (en) * | 1996-09-05 | 2000-06-13 | Eli Lilly And Company | Selective β3 adrenergic agonists |
| ES2171839T3 (es) | 1996-09-05 | 2002-09-16 | Lilly Co Eli | Analogos de carbazol como agonistas adrenergicos selectivos de beta3. |
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| WO1999009001A1 (fr) * | 1997-08-19 | 1999-02-25 | Kissei Pharmaceutical Co., Ltd. | Derives de phenylethanolaminotetraline et bronchodilatateurs |
| CO5011072A1 (es) * | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
| FR2784582B3 (fr) * | 1998-10-14 | 2000-11-24 | Sanofi Sa | Nouvelle utilisation therapeutique de composes a activite beta-3-agoniste |
| EP1623705A1 (de) * | 2004-07-09 | 2006-02-08 | Sanofi-Aventis | Verwendung von Phenyläthanolaminotetralinen zur Herstellung von Anxiolytika |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL79323A (en) * | 1985-07-10 | 1990-03-19 | Sanofi Sa | Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them |
| IT1204416B (it) * | 1986-06-27 | 1989-03-01 | Midy Spa | Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini |
| US5235103A (en) * | 1987-08-12 | 1993-08-10 | Sanofi | Process for the preparation of phenylethanolaminotetralins |
| EP0303546B1 (de) * | 1987-08-12 | 1994-12-28 | Sanofi | Verfahren zur O-Alkylierung von N-(Hydroxy)aralkylphenylethanolamin |
| US5198586A (en) * | 1987-08-12 | 1993-03-30 | Sanofi | Process for the preparation of phenylethanolaminotetralins |
| US5312961A (en) * | 1989-02-14 | 1994-05-17 | Elf Sanofi | 2-amino-7-hydroxytetralin carboxylalkyl ethers |
| IE65511B1 (en) * | 1989-12-29 | 1995-11-01 | Sanofi Sa | New phenylethanolaminomethyltetralins |
-
1993
- 1993-05-28 EP EP93401375A patent/EP0627407A1/de not_active Withdrawn
-
1994
- 1994-05-26 EP EP94401163A patent/EP0626367B1/de not_active Expired - Lifetime
- 1994-05-26 DE DE69402463T patent/DE69402463T2/de not_active Expired - Lifetime
- 1994-05-26 AT AT94401163T patent/ATE151405T1/de active
- 1994-05-26 DK DK94401163.4T patent/DK0626367T3/da active
- 1994-05-26 ES ES94401163T patent/ES2103113T3/es not_active Expired - Lifetime
- 1994-05-30 JP JP11718294A patent/JP3939369B2/ja not_active Expired - Fee Related
- 1994-05-31 US US08/250,830 patent/US5488151A/en not_active Expired - Fee Related
-
1997
- 1997-06-11 GR GR970401373T patent/GR3023729T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0627407A1 (de) | 1994-12-07 |
| US5488151A (en) | 1996-01-30 |
| ES2103113T3 (es) | 1997-08-16 |
| EP0626367A1 (de) | 1994-11-30 |
| DE69402463D1 (de) | 1997-05-15 |
| DE69402463T2 (de) | 1997-11-27 |
| JPH0770013A (ja) | 1995-03-14 |
| GR3023729T3 (en) | 1997-09-30 |
| EP0626367B1 (de) | 1997-04-09 |
| ATE151405T1 (de) | 1997-04-15 |
| JP3939369B2 (ja) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200000759A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| EA200301306A1 (ru) | Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение | |
| EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
| EA200400073A1 (ru) | Пирролопиримидины как ингибиторы протеинкиназы | |
| EA200001223A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| DE69713582D1 (de) | Zimtsäurederivate und deren verwendung als integrin-antagonisten | |
| ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
| RU2695274C3 (ru) | Новые композиции и способы их стабилизации | |
| DK0626367T3 (da) | (7S)-7- (2R)-2-(3-chlorphenyl)-2-hydroxyethylamino -5,6,7,8-tetrahydronapthalen-2-yloxyeddikesyre og farmaceutisk acceptable salte deraf med beta3-adrenerg agonistvirkning, farmaceutiske præparater og laboratoriereagenser som indeholder den. | |
| EA200100204A1 (ru) | Фармацевтические агенты для лечения болезни паркинсона, ганв и микроаденом | |
| TNSN03140A1 (fr) | Derives d'acides sulfoniques nouveaux. | |
| SE9903894D0 (sv) | Novel compounds | |
| SE0102055D0 (sv) | New Compounds | |
| ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
| PT1204658E (pt) | Agonistas benzofurilpiperazina de serotonina | |
| EA200100297A1 (ru) | Моногидрат гидробромида элетриптана | |
| EA200101241A1 (ru) | Производные индола | |
| DK0624569T3 (da) | MMDA-antagonister | |
| ATE45738T1 (de) | 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4-(2-oxo-1,3 dioxol-4-yl-methyl)-1-piperazinyl>-3chinolincarbons|uren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel. | |
| NO852514L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 8-alkyltio-2-piperazino-pyrimido (5,4-d) pyrimidin-derivater. | |
| EA200100984A1 (ru) | Новые кристаллические формы макролидного антибиотика | |
| KR890003378A (ko) | 혐기성균에 대해 항균작용을 갖는 나프티리딘 화합물 | |
| EA199801015A1 (ru) | Производные пиперидинуксусной кислоты и их применение при лечении тромботических нарушений | |
| KR890003755A (ko) | 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물 | |
| EA200200540A1 (ru) | Щелочные соли n-(6-алкил-2,4-диоксо-1,2,3,4-тетрагидро-5-пиримидинсульфон)-n'-изоникотиноилгидразида, которые могут обладать антимикробной и иммунотропной активностью, способ их получения, их использование в качестве иммуномодулятора и фармацевтическая композиция на их основе |